Trevi Therapeutics, Inc.
TRVIUnited States
30 filed reports · 302 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
30 reports · Mar 2019 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 23 | 2,759 | Mar 2019 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 7 | 2,113 | Dec 2019 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 237 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 139 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 17, 2026 | 472 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 13, 2025 | 177 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 125 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 120 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 18, 2025 | 322 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 6, 2024 | 129 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 8, 2024 | 128 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 7, 2024 | 130 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 20, 2024 | 318 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 9, 2023 | 133 | Open |
Financial data
302 concepts · 4,872 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial302 concepts · 4,872 facts · Dec 2017 to Jul 2026
- Cash and cash equivalents at carrying value44 · Dec 2017 to Jun 2026
- Stockholders equity (US GAAP)44 · Dec 2017 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value42 · Mar 2018 to Jun 2026
- General and administrative expense (US GAAP)42 · Mar 2018 to Jun 2026
- Income tax expense benefit42 · Mar 2018 to Jun 2026
- Increase decrease in accounts payable42 · Mar 2018 to Jun 2026
- Increase decrease in accrued liabilities42 · Mar 2018 to Jun 2026
- Net cash provided by used in operating activities42 · Mar 2018 to Jun 2026
- Net income loss42 · Mar 2018 to Jun 2026
- Nonoperating income expense42 · Mar 2018 to Jun 2026
- Operating expenses (US GAAP)42 · Mar 2018 to Jun 2026
- Operating income loss42 · Mar 2018 to Jun 2026
- Research and development expense42 · Mar 2018 to Jun 2026
- Share based compensation42 · Mar 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents41 · Dec 2017 to Jun 2026
- Net cash provided by used in financing activities40 · Mar 2018 to Jun 2026
- Operating lease payments40 · Mar 2018 to Dec 2025
- Accounts payable current39 · Dec 2018 to Jun 2026
- Accrued employee benefits current39 · Dec 2018 to Jun 2026
- Accrued liabilities current39 · Dec 2018 to Jun 2026
- Assets39 · Dec 2018 to Jun 2026
- Assets current39 · Dec 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect39 · Dec 2018 to Jun 2026
- Common stock capital shares reserved for future issuance39 · Dec 2018 to Jun 2026
Segments
Figures broken down by business line, region, product or another axis the company reports on.
No segment breakdowns.
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.